Tibra Equities Europe’s CorMedix CRMD Stock Holding History

Tibra Equities Europe’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-62,791	Closed	-$593K	–	294
2019 Q1	$593K	Buy	+62,791	New	+$566K	0.06%	247

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Tibra Equities Europe's CRMD Position: Q2 2019 in Review

Tibra Equities Europe sold out of CorMedix (CRMD) in Q2 2019, closing a stake of 62,791 shares — an estimated $593K sold.

Tibra Equities Europe first reported a position in CRMD in Q1 2019 and held it in 1 quarter. The position peaked at $593K in Q1 2019. 47 funds tracked by Wall St. Rank hold CRMD as of Q2 2019.

Tibra Equities Europe reported no remaining CorMedix position as of Q2 2019 after selling out during the quarter.
Tibra Equities Europe sold 62,791 CorMedix shares in Q2 2019, an estimated $593K.
Tibra Equities Europe first reported a position in CorMedix in Q1 2019 and held it in 1 quarter.
Tibra Equities Europe's CorMedix position peaked at $593K in Q1 2019.
47 funds tracked by Wall St. Rank held CorMedix as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.